Endocrine Abstracts

Aim: To quantify the effect of pegvisomant on glucose homeostasis, lipid profile and disease activity in acromegaly.Methods: 5 Patients with active acromegaly after surgery, radiotherapy and somatostatin analogs were included. Somatostatin analogs were withdrawn 6 weeks before starting pegvisomant and it was initially administered subcutaneously at doses of 10 mg daily. Doses were progressively increased every 3 to 4 weeks until IGF1 normalization. Gluco...